Medtronic isn’t the only medtech company facing criticism over potentially moving its headquarters overseas. Hospira is also taking flak—even though it is only rumored so far to be in talks with French company Danone for a so-called “inversion” deal.
Media outlets including The Wall Street Journal, New York Times and Bloomberg all hung recent stories on an anonymous source when it came to Lake Forest, IL–based Hospira potentially paying $5 billion for Danone’s medical nutrition business. The deal would amount to a “spinversion” that would allow Hospira to move its headquarters outside the U.S.
Help employers find you! Check out all the jobs and post your resume.
